Interestingly, cancer patients that are treated with the EGFR antagonist cetuximab frequently develop severe hypomagnesemia that is associated with a decreased expression of TRPM6 and possibly TRPM7.144, 164. Here, TRPM6 is linked to familial primary hypomagnesemia.